Art

J-GLOBAL ID：201502245311615701   Reference number：15A0374130

Field practice study of half-dose sorafenib treatment on safety and efficacy for hepatocellular carcinoma: A propensity score analysis

肝細胞癌への安全性と有効性に対する半用量ソラフェニブ治療に関するフィールドワーク研究:傾向スコア分析

Author (14)： MORIMOTO Manabu (Gastroenterological Center, Yokohama City Univ. Medical Center, Yokohama, Japan; Dep. of Hepatobiliary and ...) ,  NUMATA Kazushi ,  KONDO Masaaki ,  KOBAYASHI Satoshi ,  OHKAWA Shinichi ,  HIDAKA Hisashi ,  NAKAZAWA Takahide ,  OKUWAKI Yusuke ,  OKUSE Chiaki ,  MATSUNAGA Kotaro ,  SUZUKI Michihiro ,  MORITA Satoshi ,  TAGURI Masataka ,  TANAKA Katsuaki
Material： Hepatology Research  (Hepatol Res)
Volume： 45  Issue： 3  Page： 279-287  Publication year： Mar. 2015 
JST Material Number： W1284A  ISSN： 1386-6346  Document type： Article
Article type： 原著論文  Country of issue： Australia (AUS)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *dose reduction ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0374130&from=J-GLOBAL&jstjournalNo=W1284A") }}

JST classification (3)： Tumors(=neoplasms)of digestive system  (GH04000D) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Sorafenib

Reference (29)：

• El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-73.
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
• Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004; 64: 7099-109.
• Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
• Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.

Terms in the title (9)： 肝細胞癌 ,  安全性 ,  用量 ,  ソラフェニブ ,  治療 ,  フィールドワーク ,  研究 ,  傾向スコア ,  分析